文献速递浆细胞疾病

优化美法仑、泼尼松和硼替佐米治疗初治多发性骨髓瘤的随机II期研究(JCOG1105)

Randomised phase II study to optimise melphalan, prednisolone, and bortezomib in untreated multiple myeloma (JCOG1105).
PubMed 文献 · Br J Haematol · 2020-06-24

这项随机II期研究在不可移植的初治多发性骨髓瘤患者中比较两种MPB方案。A组(首周期每周两次硼替佐米)较B组(每周一次)有更高的完全缓解率(18.6% vs 6.7%)和更长的中位无进展生存期(2.5年 vs 1.4年),但血液学毒性更高。A组被认为是更有前景的方案。

要点

  • A组完全缓解率18.6%,B组6.7%。
  • A组中位无进展生存期2.5年,B组1.4年(HR 1.93)。
  • A组3级及以上中性粒细胞减少和血小板减少发生率更高。

核心结论

  • A组是更有前景的方案,提示首周期每周两次硼替佐米及更高的硼替佐米和美法仑累积剂量影响改良MPB方案的疗效。

研究设计与样本

  • 随机II期研究,纳入不可移植的初治多发性骨髓瘤患者,随机分配至A组或B组,共91例随机,88例符合纳入标准。

主要发现

  • A组和B组的中位硼替佐米累积剂量分别为45.8和35.1 mg/m2。
  • A组完全缓解率为18.6%(95%CI 8.4-33.4),B组为6.7%(95%CI 1.4-18.3)。
  • A组中位无进展生存期为2.5年,B组为1.4年,风险比(HR)为1.93(95%CI 1.09-3.42)。
  • A组和B组常见的3级及以上血液学毒性分别为中性粒细胞减少(64.4% vs 28.3%)和血小板减少(35.6% vs 10.9%)。
  • A组2级和3级周围神经病变发生率分别为24.4%和2.2%,B组分别为8.7%和0%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We conducted a randomised phase II study to determine the optimal dose and schedule of melphalan, prednisone, and bortezomib (MPB) (jRCTs031180097). Transplant-ineligible untreated multiple myeloma patients were randomised to Arm A (twice weekly bortezomib in one six-week cycle followed by eight five-week cycles of four times once weekly bortezomib with melphalan and prednisolone on days 1-4) or Arm B (nine four-week cycles of three times once weekly bortezomib with melphalan and prednisolone on days 1-4). The primary end-point was complete response (CR) rate. Of 91 patients randomised to two arms, 88 were eligible. The median cumulative bortezomib doses were 45·8 and 35·1 mg/m2 , CR rate was 18·6% [95% confidence interval (CI) 8·4-33·4] and 6·7% (95% CI 1·4-18·3), and the median progression-free survival (PFS) was 2·5 and 1·4 years in Arms A and B [hazard ratio (HR) 1·93 (95% CI 1·09-3·42)], respectively. Frequent grade ≥3 haematologic toxicities in Arms A and B were neutropenia (64·4% vs. 28·3%) and thrombocytopenia (35·6% vs. 10·9%). Grade 2/3 peripheral neuropathy was observed in 24·4/2·2% in Arm A and 8·7/0% in Arm B. In conclusion, Arm A was the more promising regimen, suggesting that the twice weekly schedule of bortezomib in the first cycle and higher cumulative dose of both bortezomib and melphalan influences the efficacy of modified MPB.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Maruyama D, Iida S, Ogawa G, et al. Randomised phase II study to optimise melphalan, prednisolone, and bortezomib in untreated multiple myeloma (JCOG1105). Br J Haematol. 2020. PMID: 32583431. doi:10.1111/bjh.16878

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。